Medexus Pharmaceuticals Inc is making waves on the TSX with a significant price jump.
Medexus Pharmaceuticals Inc (MDP.TO) is experiencing a remarkable surge in its stock price, rising by 8.47% in today's trading session. As investors take notice, the company's market cap now stands at approximately CA$160 million, reflecting growing confidence in its future prospects.
Investor takeaway: The recent price increase suggests renewed investor interest in Medexus, potentially driven by positive sentiment surrounding its product performance.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
-1.20%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 37.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+37.3% Upside
Current Price
C$4.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
41.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.26 | C$4.44 – C$6.23 |
| 60 trading days | C$5.59 | C$4.40 – C$7.10 |
| 90 trading days | C$5.93 | C$4.42 – C$7.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medexus Pharmaceuticals Inc stock rises 8.47% today
Advertisement
This increase marks a significant uptick in investor interest, potentially signaling a turnaround for the company.
Bull case
The strong performance of GRAFAPEX (treosulfan) for Injection has been a key driver for Medexus. This indicates robust demand and the potential for continued revenue growth, which is encouraging for investors.
Bear case
Despite today's gains, Medexus still faces challenges. The company has a negative profit margin and needs consistent product performance to maintain investor confidence.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
